esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
Published 3 years ago • 2.3K plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
2:05
esmo 2020 highlights on nivolumab cabozantinib as 1st line therapy for arcc: the checkmate 9er study
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
2:35
esmo 2020 highlights on 1st line durvalumab and tremelimumab for mpdac: the pa.7 study
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
3:05
esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study
-
2:27
esmo 2020 highlights on neoadjuvant ici in early tnbc: the impassion031 study
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
6:37
highlights from esmo 2020 in gynecological cancers
-
3:07
esmo 2020 highlights on blocking pi3k/akt signalling pathway in mcrpc: the ipatential150 study
-
11:50
esmo 2020 expert video report on the combination of immuno and targeted therapies in melanoma
-
2:26
#esmo21 highlights on pembro chemo in 1st-line metastatic cervical cancer: the keynote-826 study
-
2:17
#esmo22 highlights on pembrolizumab with crt in locally advanced hnscc: the keynote-412 study
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
7:36
esmo 2020 expert video report on atezolizumab in upfront treatment of tnbc
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
2:29
esmo preceptorships – introductory video
-
5:26
updates in 1l urothelial cancer from esmo 2020
-
3:49
esmo highlights: genitourinary cancers